| 1 | technical storage or access | | | | | | | 5 | 0.55% |
| 2 | storage or access is | | | | | | | 3 | 0.33% |
| 3 | of complex patient care | | | | | | | 2 | 0.22% |
| 4 | by the subscriber or | | | | | | | 2 | 0.22% |
| 5 | market entry strategies in | | | | | | | 2 | 0.22% |
| 6 | accelerate access to innovative | | | | | | | 2 | 0.22% |
| 7 | access to innovative treatment | | | | | | | 2 | 0.22% |
| 8 | to innovative treatment and | | | | | | | 2 | 0.22% |
| 9 | the technical storage or | | | | | | | 2 | 0.22% |
| 10 | the rare disease community | | | | | | 2 | 0.22% |
| 11 | necessary for the legitimate | | | | | | | 2 | 0.22% |
| 12 | the subscriber or user | | | | | | | 2 | 0.22% |
| 13 | entry strategies in central | | | | | | | 2 | 0.22% |
| 14 | storage or access that | | | | | | | 2 | 0.22% |
| 15 | is used exclusively for | | | | | | | 2 | 0.22% |
| 16 | innovative treatment and care | | | | | | | 2 | 0.22% |
| 17 | that is used exclusively | | | | | | | 2 | 0.22% |
| 18 | access that is used | | | | | | | 2 | 0.22% |
| 19 | or access that is | | | | | | | 2 | 0.22% |
| 20 | fabry disease which were | | | | | | | 1 | 0.11% |
| 21 | diseases hattr ahp ph1 | | | | | | | 1 | 0.11% |
| 22 | ph1 fabry disease which | | | | | | | 1 | 0.11% |
| 23 | hattr ahp ph1 fabry | | | | | | | 1 | 0.11% |
| 24 | programs for rare diseases | | | | | | | 1 | 0.11% |
| 25 | ahp ph1 fabry disease | | | | | | | 1 | 0.11% |
| 26 | for rare diseases hattr | | | | | | | 1 | 0.11% |
| 27 | rare diseases hattr ahp | | | | | | | 1 | 0.11% |
| 28 | home services about contact | | | | | | | 1 | 0.11% |
| 29 | for similar marketing purposes | | | | | | | 1 | 0.11% |
| 30 | rarecare home services about | | | | | | | 1 | 0.11% |
| 31 | similar marketing purposes manage | | | | | | | 1 | 0.11% |
| 32 | highly innovative drugs in | | | | | | | 1 | 0.11% |
| 33 | manage vendorcount vendors read | | | | | | | 1 | 0.11% |
| 34 | biopharmaceutical industry she launched | | | | | | | 1 | 0.11% |
| 35 | industry she launched and | | | | | | | 1 | 0.11% |
| 36 | she launched and obtained | | | | | | | 1 | 0.11% |
| 37 | launched and obtained reimbursement | | | | | | | 1 | 0.11% |
| 38 | and obtained reimbursement for | | | | | | | 1 | 0.11% |
| 39 | numerous orphan and highly | | | | | | | 1 | 0.11% |
| 40 | orphan and highly innovative | | | | | | | 1 | 0.11% |